Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02283762 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 121
- Enrollment target
NCT02283762 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 121 participants.
The verdict
NCT02283762, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 121 participants
- Enrollment target
Study Summary
To investigate if Riociguat is effective in the treatment of systemic sclerosis
Interventions
- DRUG Placebo
- DRUG Riociguat (Adempas, BAY63-2521)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2015-01-15 |
| Est. Completion | 2019-03-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02283762
The ClinicalTrials.gov registry entry for NCT02283762 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02283762 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02283762 about?
NCT02283762 is a clinical study titled "Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis". To investigate if Riociguat is effective in the treatment of systemic sclerosis
What is the current status of trial NCT02283762?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 121 participants. The study started on 2015-01-15. Estimated completion is 2019-03-28.
What interventions are being tested in trial NCT02283762?
The interventions under investigation include: Placebo (DRUG), Riociguat (Adempas, BAY63-2521) (DRUG).
Who is sponsoring clinical trial NCT02283762?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.